Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).

Article  PubMed  Google Scholar 

Bergengren, O. et al. 2022 update on prostate cancer epidemiology and risk factors — a systematic review. Eur. Urol. 84, 191–206 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Litwin, M. S. & Tan, H.-J. The diagnosis and treatment of prostate cancer. JAMA 317, 2532–2542 (2017).

Article  PubMed  Google Scholar 

Shafi, A. A., Yen, A. E. & Weigel, N. L. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol. Ther. 140, 223–238 (2013).

Article  CAS  PubMed  Google Scholar 

Tombal, B. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann. Oncol. 23, x251–x258 (2012).

Article  PubMed  Google Scholar 

Zhang, Y. & Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol. Immunol. 17, 807–821 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395–405 (2020).

Article  CAS  PubMed  Google Scholar 

Sharma, P. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial. Cancer Cell 38, 489–499.e3 (2020).

Article  CAS  PubMed  Google Scholar 

Graff, J. N. et al. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J. Immunother. Cancer 8, e000642 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Lee, P. & Gujar, S. Potentiating prostate cancer immunotherapy with oncolytic viruses. Nat. Rev. Urol. 15, 235–250 (2018).

Article  CAS  PubMed  Google Scholar 

Zhang, J. et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553, 91–95 (2018).

Article  CAS  PubMed  Google Scholar 

Bhatia, V. et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat. Commun. 14, 2041 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pachynski, R. K. et al. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Immunother. Cancer 9, e002903 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Brown, J. S., Sundar, R. & Lopez, J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br. J. Cancer 118, 312–324 (2018).

Article  CAS  PubMed  Google Scholar 

Goel, S. et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471–475 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin, Y. X. et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci. Transl. Med. 13, eaba9772 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morel, K. L. et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat. Cancer 2, 444–456 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi, Z. et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. Nat. Commun. 13, 182 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patnaik, A. et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov. 7, 750–765 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gujar, S. A., Pan, D. A., Marcato, P., Garant, K. A. & Lee, P. W. Oncolytic virus-initiated protective immunity against prostate cancer. Mol. Ther. 19, 797–804 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozga, A. J., Chow, M. T. & Luster, A. D. Chemokines and the immune response to cancer. Immunity 54, 859–874 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cha, E. & Fong, L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J. Clin. Oncol. 29, 3677–3685 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A. & Bluestone, J. A. CD28 costimulation: from mechanism to therapy. Immunity 44, 973–988 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

He, Q., Jiang, X., Zhou, X. & Weng, J. Targeting cancers through TCR-peptide/MHC interactions. J. Hematol. Oncol. 12, 139 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giles, J. R., Globig, A.-M., Kaech, S. M. & Wherry, E. J. CD8+ T. cells in the cancer-immunity cycle. Immunity 56, 2231–2253 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug. Discov. 18, 197–218 (2019).

Article  CAS  PubMed  Google Scholar 

Majidpoor, J. & Mortezaee, K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clin. Immunol. 226, 108707 (2021).

Article  CAS  PubMed  Google Scholar 

Brea, L. & Yu, J. Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer. Trends Endocrinol. Metab. https://doi.org/10.1016/j.tem.2024.12.003 (2025).

Zhang, H. et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J. Exp. Clin. Cancer Res. 40, 184 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian, S. L., Weiner, G. J. & Pardoll, D. M. Cancer immunotherapy comes of age. J. Clin. Oncol. 29, 4828–4836 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thakur, A., Vaishampayan, U. & Lum, L. G. Immunotherapy and immune evasion in prostate cancer. Cancers 5, 569–590 (2013).

Article  CAS